Global Hepatitis C market is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family Flaviviridae and genus hepacivirus. It has a positive-sense, single-stranded RNA molecule enveloped by a lipid bilayer. Hepatitis C can lead to acute infection or chronic infection. Nearly 80 percent of the infected individuals suffering from acute infection are asymptomatic. Symptoms manifested in the rest include nausea, dark urine, fever, anorexia, gray-colored faces, abdominal pain, and joint pain. Nearly 20 percent of infected individuals develop jaundice, which is characterized by the yellowing of skin and eyes. Nearly 15-45 percent of acutely infected individuals recover from the infection spontaneously within the first six months of infection. This happens because the immune system mediated the clearance of the virus from the body. The remaining 55-85 percent of infected individuals who fail to clear the virus within six months develop chronic hepatitis C phase. Chronic infection can lead to mild-to-moderate symptoms or chronic symptoms such as liver fibrosis, liver cirrhosis, and hepatic cancer. The World Health Organization (WHO) estimates that globally, 130-150 million people suffer from chronic hepatitis B. It also reported that every year 350,000-500,000 infected individuals die because of hepatitis C-related hepatic disorders. Currently, there is no vaccine for the prevention of hepatitis C infection; however, various treatment options for hepatitis C infection are available.
The report analysts forecast the Global Hepatitis C market to grow at a CAGR of 19.20 percent over the period 2013-2018.
Covered in this Report:
The report analysts forecast the Global Hepatitis C market to grow at a CAGR of 19.20 percent over the period 2013-2018.
Covered in this Report:
- This report covers the present scenario and the growth prospects of the Global Hepatitis C market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through sales of various drugs administered to treat chronic hepatitis caused by genotype 1-6 of hepatitis C virus.
- The report, Global Hepatitis C Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Hepatitis C market landscape and its growth prospects in the coming years.
To Read Other Reports of This Category:
http://www.radiantinsights.com/catalog/healthcare
http://www.radiantinsights.com/catalog/healthcare
The report includes a discussion of the key vendors operating in this market.
Key Regions
Key Regions
- Americas
- APAC
- EMEA
Key Vendors
- F. Hoffmann-La Roche
- Gilead Sciences
- Johnson & Johnson
- Merck
- Vertex Pharmaceuticals
Other Prominent Vendors
- Abbvie
- Achillion Pharmaceuticals
- Bristol-Myers Squibb
- Mitsubishi Tanabe Pharma
- Novartis
Market Driver
- Increase in Injection Drug Users
- For a full, detailed list, view our report
Market Challenge
- Side-effects of Current Therapy
- For a full, detailed list, view our report
Market Trend
- Emergence of Interferon-free Therapies
- For a full, detailed list, view our report
No comments:
Post a Comment